DxCheck Unveils AI-Powered Workspace Tailored to HCP Specialties
For pharma marketers, the DxPro portal opens up a new avenue for HCP engagement.
DxCheck has launched a new offering expanding its AI-powered health information capabilities to clinicians.
The company’s eponymous flagship product centers on patients and caregivers, who can visit DxCheck to find clinically vetted info about symptoms, risk factors, potential conditions and diagnoses, and to track their health and treatment progress.
The newly unveiled DxPro portal extends that AI-fueled support to U.S. healthcare professionals. After verifying their identity via NPI, HCPs can use the workspace to access a range of information and resources specific to their clinical specialty: They can ask questions that’ll be answered with citations from published literature, keep up with a feed of relevant regulatory, trial and publication updates, view patients’ reviews of certain treatments and more, according to the launch announcement.
Additionally, through DxPro, HCPs can accept opportunities to review DxCheck’s patient-facing content for accuracy.
The workspace is available now, with free access for verified U.S. clinicians.
For pharma marketers, who are already able to activate patient-focused messaging on DxCheck, DxPro opens up a new avenue for HCP engagement. The new offering therefore allows messages to follow a specific condition from patient to clinician, according to the company, which noted to solli that it now offers four ways to engage HCPs at moments of clinical decision, including via the DxPro portal, omnichannel extension, in-EMR delivery and signal-led prioritization.
solli’s Final Thoughts
There’s a growing call among pharma marketers for the ability to reach clinicians closer to moments of clinical decision-making.
Placing messaging within specialty-specific digital workflows—that also offer relevant support and resources to overstretched HCPs—and connecting patient and HCP engagement around the same condition could enable more coordinated, impactful messaging across the care journey.
But, as always when pharma and new technologies collide, success will depend on delivering credible, relevant content without disrupting clinicians’ work, overstepping privacy or regulatory bounds or undermining trust.
